Novartis will present new data on Cosentyx

[Fred]

Novartis have announced they will be presenting data on Cosentyx at at the 73rd Annual Meeting of American Academy of Dermatology that shows superiority over Stelara for psoriasis.

Quote:

---

Novartis announced today that new results for Cosentyx (secukinumab) in moderate-to-severe plaque psoriasis, including detailed findings from the head-to-head CLEAR study and long-term data from the Phase III program, will be presented as late breaking research at the 73rd Annual Meeting of American Academy of Dermatology (AAD), from 20 - 24 March in San Francisco, California, USA. In total, 25 posters from the Novartis Dermatology portfolio will be highlighted at this leading congress.

New data from the CLEAR study will include results that demonstrate Cosentyx is superior to Stelara (ustekinumab) in clearing skin (PASI 90 and PASI 100) at Week 16. CLEAR is the first Phase III psoriasis study designed with a PASI 90 objective, which is considered an important measure of treatment success by the European Medicines Agency and an optimal treatment goal for patients.

In addition, new long-term results for Cosentyx up to two years from the Phase III program will be highlighted for the first time at the congress. The data comes from an extension of the pivotal FIXTURE and ERASURE studies. In the FIXTURE study, Cosentyx cleared the skin of 72% psoriasis patients compared to 31% for Enbrel (etanercept) at Week 16.

"We are excited to present new late-breaking research at AAD, following the back-to-back regulatory approvals received earlier this year," said Vasant Narasimhan, Global Head of Development, Novartis Pharmaceuticals. "Our commitment is to keep demonstrating more evidence on the ability of Cosentyx to clear psoriasis skin, to inform physicians and give hope to people living with this life-long disease who need treatments that provide long-term relief."

In January 2015, Cosentyx (at a dose of 300 mg) became the first and only interleukin-17A (IL-17A) inhibitor approved in Europe as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adult patients, and in the US as a treatment for moderate-to-severe plaque psoriasis in adult psoriasis patients who are candidates for systemic therapy (a drug that is absorbed into the bloodstream and distributed to all parts of the body) or phototherapy (light therapy). In addition to the EU and the US, Cosentyx has been approved in Switzerland, Chile, Australia and Canada for the treatment of moderate-to-severe plaque psoriasis and in Japan for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA).

Source: novartis.com

[Quest4Cure]

Sounds very promising....cosentyx. Palmoplantar P. is very difficult to treat. This is giving more patients hope as more new therapy treatments are developed than ever before. Psoriasis doesn't need to be so elusive to treat as it was in the past. ( helps some contact dermatitis too)
So many who suffer from P. around the world have a better chance to find a drug that can finally put psoriasis of many types in remission.

More big farms today have invested millions for the race for "THE DRUG"  that will get to market first. In fact as little as 5 years ago few big pharms were just starting out with clinical trials for drugs for Psoriasis. Boy I wish I had the vision to invest back then.

I guess that means that Derms are getting smarter too! There are many that specialize in Psoriasis treatments today, where in the past you were given a tube of steroids , UVB therapy and left on you own.

Movin on....I always wonder what my grandmother would say if she had these new P. Drugs available to her. Her skin was ravaged a thick gruesome mess. As a child I was frightened of her scary skin, not knowing I had the very same thing at a earlier stage. Just lucky I guess!

Viva La Vida!  
Hope I didn't get too messy.....